{"created":"2023-05-15T16:13:19.932661+00:00","id":43862,"links":{},"metadata":{"_buckets":{"deposit":"e08947f6-bc03-42a6-b3de-68087888193f"},"_deposit":{"created_by":25,"id":"43862","owners":[25],"pid":{"revision_id":0,"type":"depid","value":"43862"},"status":"published"},"_oai":{"id":"oai:shinshu.repo.nii.ac.jp:00043862","sets":["2668"]},"author_link":["170737","170735","170733","170736","170734"],"item_20002_biblio_info_27":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"1218","bibliographicPageStart":"1212","bibliographicVolumeNumber":"97","bibliographic_titles":[{"bibliographic_title":"ACTA DERMATO-VENEREOLOGICA"}]}]},"item_20002_creator_3":{"attribute_name":"作成者(その他言語)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ashida, Atsuko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sakaizawa, Kaori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uhara, Hisashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okuyama, Ryuhei"}],"nameIdentifiers":[{}]}]},"item_20002_date_19":{"attribute_name":"日付","attribute_value_mlt":[{"subitem_date_issued_datetime":"2018-11-05","subitem_date_issued_type":"Created"}]},"item_20002_description_14":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2–4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.","subitem_description_type":"Other"}]},"item_20002_description_20":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_20002_description_22":{"attribute_name":"その他の資源識別子","attribute_value_mlt":[{"subitem_description":"ACTA DERMATO-VENEREOLOGICA. 97:1212-1218(2018)","subitem_description_type":"Other"}]},"item_20002_full_name_16":{"attribute_name":"公開者(その他言語)","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"ACTA, DERMATO-VENEREOLOGICA"}]}]},"item_20002_identifier_23":{"attribute_name":"資源識別子URI","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/10091/00021019"}]},"item_20002_relation_31":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.ncbi.nlm.nih.gov/pubmed/28681063","subitem_relation_type_select":"PMID"}}]},"item_20002_relation_32":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.2340/00015555-2748","subitem_relation_type_select":"DOI"}}]},"item_20002_rights_50":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Journal Compilation © 2017 Acta Dermato-Venereologica. This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta"},{"subitem_rights":"Journal Compilation © 2017 Acta Dermato-Venereologica. This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta"}]},"item_20002_source_id_25":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0001-5555","subitem_source_identifier_type":"ISSN"}]},"item_20002_version_type_51":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"url":{"url":"https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download&item_id=20261&item_no=1&attribute_id=65&file_no=1"}}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"melanoma","subitem_subject_scheme":"Other"},{"subitem_subject":"circulating tumour DNA","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-programmed cell death-1 antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"BRAF","subitem_subject_scheme":"Other"},{"subitem_subject":"NRAS","subitem_subject_scheme":"Other"},{"subitem_subject":"droplet digital PCR","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients"}]},"item_type_id":"20002","owner":"25","path":["2668"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-09-04"},"publish_date":"2020-09-04","publish_status":"0","recid":"43862","relation_version_is_last":true,"title":["Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2023-05-15T18:20:31.676852+00:00"}